Eliminating Hepatitis C by 2030: what’s stigma got to do with it?

Australie

$0

gratuit

RACGP CPD Program

1.5 hrs

Maladie infectieuse

3 Credits

Description du cours

Hepatitis C virus (HCV) is a potentially life-threatening virus that primarily affects the liver. In Australia, over 170,000 people were estimated to have chronic HCV infection at the start of 2017 and 130,000 were still living with HCV at the end of 2018. The introduction of direct-acting antiviral (DAA) therapies, which can cure HCV in the majority of patients, represents a major advance and all Australians living with HCV should now be considered for DAA therapy. However, stigma represents a key barrier to diagnosis and treatment. As a result, Australia’s Fifth National Hepatitis C Strategy 2018–2022 has identified stigma and discrimination as one of five key priority areas for action.


This program is supported by an independent educational grant provided by Gilead sciences.

Détails du cours

Date d'expiration : 2022-12-31

Métiers: Médecin

Faculté

Prof Carla Treloar, Director of the Centre for Social Research in Health and the Social Policy Research Centre, UNSW

Dr Anne Balcomb, GP, Orange

Dr David Baker, GP, Sydney

Accréditation

This Active Learning Module has been approved by RACGP CPD Program for 3 CPD points.

Activity no. 226172

Members are able to claim CPD activity points for 3 points through ‘Quick log’ on their RACGP CPD Dashboard.

Objectif(s) d'apprentissage

On completion of this program, participants will be better able to:

  • Recognise the different ways in which stigma related to hepatitis C virus (HCV) infection can present in the primary care setting
  • Describe the ways in which stigma can have a negative impact on outcomes for patients with HCV infection
  • Understand the ways in which addressing stigma in primary care can help achieve the goal of eliminating HCV by 2030
  • Confidently apply effective communication techniques and tools to overcome stigma and optimise outcomes for patient with HCV infection